Rapport Therapeutics

RAPP

Market cap $1.15B

SAN FRANCISCO & AUSTIN, Texas & EDINBURGH, Scotland--(BUSINESS WIRE)-- #AI--Rapport Acquires Aquifer Motion, Becoming the First Company to Offer Real-Time, AI-Powered Avatars with Full-Body Animation.

Rapport Therapeutics, Inc. (NASDAQ:RAPP ) TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit September 17, 2025 11:20 AM EDT Company Participants Abraham Ceesay - CEO, President, Treasurer & Director Troy Ignelzi - Chief Financial Officer Conference Call Participants Joseph Thome - TD Cowen, Research Division Presentation Joseph Thome TD Cowen, Research Division Hi, everyone, and thank you for joining us at our 2025 Fifth Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit. I'm Joe Thome, one of the senior biotech analysts here on the team at TD Cowen.

Rapport Therapeutics stock jumps 62% in a week as mid-stage study of RAP-219 meets goals in drug-resistant epilepsy patients.

Crédit Agricole Normandie Seine : Rapport financier semestriel 2025 Le rapport financier semestriel au 30/06/2025 de la Caisse régionale de Crédit Agricole Mutuel Normandie Seine a été déposé auprès de l'Autorité des Marchés Financiers (AMF). Ce rapport comprend les éléments suivants : Examen de la situation financière et résultats Informations prudentielles et facteurs de risques Présentation des comptes consolidés Rapport des Commissaires aux Comptes sur les comptes consolidés Attestation du responsable de l'information financière Ce document en version française est consultable sur le site Internet du Crédit Agricole Normandie Seine : rubrique "Informations réglementées" ou sur le lien suivant : https://www.credit-agricole.fr/ca-normandie-seine/particulier/informations/informations-reglementees-maj.html Attachment 04.C1 - CR883 - Rapport Word - Groupe C Semestriel_Vdef

BOSTON and SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in the following upcoming investor conference.

Rapport stock (NASDAQ: RAPP) cratered 18% on Wednesday as the market delivered a harsh verdict on its latest funding strategy. The catalyst was as predictable as it was painful.

BOSTON and SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced the pricing of an underwritten public offering of 9,615,385 shares of its common stock at a public offering price of $26.00 per share.

BOSTON and SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock. All of the shares in the proposed offering are being offered by Rapport. In addition, Rapport intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Rapport stock (NASDAQ: RAPP) exploded on Monday, climbing nearly 200% in just one trading session. The jump came after a mix of excitement over upcoming clinical trial data and growing confidence that this small but ambitious company might be onto something big.

Rapport Therapeutics stock catapulted Monday after its drug reduced seizures in patients with a hard-to-treat form of epilepsy.